Navigation Links
Medicago succesfully expresses VLP antigen for A H1N1 strain
Date:5/12/2009

QUEBEC CITY, May 12 /PRNewswire-FirstCall/ - Medicago Inc. (TSX-V: MDG), a biotechnology company focused on developing highly effective and affordable vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), today announced that it has successfully expressed a new VLP antigen ("H1 VLP") from the influenza A (H1N1) strain that caused the recent Influenza outbreak in North America and other countries. The antigen was expressed within 14 days of receiving the DNA sequence with the Company's VLP vaccine technology and Proficia(TM) manufacturing technology.

Initial results show that the new H1 VLP is comparable to other VLPs recently expressed by Medicago such as the New Caledonia strain (H1N1) and Brisbane strain (H1N1). The primary goal of this initiative was to confirm, in a real case-scenario, Medicago's initial development timelines. Medicago requires the genetic sequence of the virus, limiting delays that may happen with traditional systems. The H1 VLP will be purified in preparation for an immunogenicity study in mice. The Company expects results from this study in June, with the goal of confirming the immunogenic potential of this H1 VLP.

"We are thrilled with these initial results. They demonstrate that we can rapidly express an antigen from a new influenza strain without modifying our current technology and could potentially be a first responder solution in the face of a pandemic," said Louis-Philippe Vezina, Chief Scientific Officer of Medicago. "Our ultimate goal is to provide a rapid approach to vaccine production allowing for immediate access to the antigens of emerging influenza strains. Current influenza vaccine manufacturing technologies can take up to six months to produce a vaccine for a new strain. With our proprietary technology we believe we can potentially cut development time up to five months."

About Medicago

Medicago is committed to provide highly effective and affordable vaccines based on proprietary Virus-Like Particle (VLP) and manufacturing technologies. Medicago is developing VLP vaccines to protect against H5N1 pandemic influenza, using a transient expression system which produces recombinant vaccine antigens in non-transgenic plants. This technology has potential to offer advantages of speed and cost over competitive technologies. It could deliver a vaccine for testing in about a month after the identification and reception of genetic sequences from a pandemic strain. This production time frame has the potential to allow vaccination of the population before the first wave of a pandemic strikes and to supply large volumes of vaccine antigens to the world market. Additional information about Medicago is available at www.medicago.com.

Forward Looking Statements

This press release contains forward-looking statements which reflect Medicago's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. Medicago disclaims any obligation to update these forward-looking statements.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release


'/>"/>
SOURCE Medicago Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Medicago initiates work on Swine Flu strain
2. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
3. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
4. Antigen Discovery Inc. Awarded a SBIR Phase II Grant to Commercialize Novel Antigens for Serodiagnostic Products and Vaccine Development
5. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
6. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
7. Scientists develop strategy to rapidly describe outbreak strains with next-generation DNA sequencing
8. Stretching silicon: A new method to measure how strain affects semiconductors
9. NIST stress tests probe nanoscale strains in materials
10. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
11. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Alex,s Lemonade Stand ... that that it will open a state-of-the-art bioinformatics lab, ... cancer research. This announcement comes as Liz Scott ... the National Cancer Moonshot Summit in Washington, ... Biden as a participant and advocate of pediatric cancer ...
(Date:6/27/2016)...  Global demand for enzymes is forecast to ... $7.2 billion.  This market includes enzymes used in ... production, animal feed, and other markets) and specialty ... and beverages will remain the largest market for ... products containing enzymes in developing regions.  These and ...
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
Breaking Biology Technology:
(Date:6/27/2016)... -- Research and Markets has announced the addition of ... their offering. The report forecasts ... grow at a CAGR of 12.28% during the period 2016-2020. ... market analysis with inputs from industry experts. The report covers the ... report also includes a discussion of the key vendors operating in ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... , June 22, 2016   ... management and verification solutions, has partnered with ... software solutions for Visitor Management, Self-Service Kiosks ... provides products that add functional enhancements to ... provides corporations and venues with an automated ...
Breaking Biology News(10 mins):